Search research articles
Contact Us
Filters
Showing results (61-70 of 212) with videos related to
Page
of 22
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 3, 2006
Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes
Gary J Schiller, James Slack, John D Hainsworth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 20, 2008
Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes
Mikkael A Sekeres, Jaroslaw P Maciejewski, Aristotle A N Giagounidis, et al.
British Journal of Haematology
|
June 25, 2013
Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes
Rami S Komrokji, Azra Raza, Jeffrey E Lancet, et al.
American Journal of Hematology
|
August 25, 2019
Driver mutation-specific clinical and genomic correlates differ between primary and secondary myelofibrosis
Andrew T Kuykendall, Chetasi Talati, Eric Padron, et al.
American Journal of Hematology
|
November 4, 2018
Genetically inspired prognostic scoring system (GIPSS) outperforms dynamic international prognostic scoring system (DIPSS) in myelofibrosis patients
Andrew T Kuykendall, Chetasi Talati, Eric Padron, et al.
Plos One
|
April 18, 2012
Erythropoietin receptor signaling is membrane raft dependent
Kathy L McGraw, Gwenny M Fuhler, Joseph O Johnson, et al.
American Journal of Hematology
|
April 26, 2014
Phase II clinical study of erlotinib for treatment of myelodysplastic syndromes
Rami S Komrokji, Eric Padron, Daohai Yu, et al.
Cancer Control : Journal of the Moffitt Cancer Center
|
January 24, 2007
Cost effectiveness of lenalidomide in the treatment of transfusion-dependent myelodysplastic syndromes in the United States
Thomas F Goss, Agota Szende, Caroline Schaefer, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
August 14, 2016
Eltrombopag Use in Patients With Chronic Myelomonocytic Leukemia (CMML): A Cautionary Tale
Hanadi Ramadan, Vu H Duong, Najla Al Ali, et al.
Leukemia & Lymphoma
|
April 21, 2020
A sequential two-stage dose escalation study of eltrombopag in patients with myelodysplastic syndrome and thrombocytopenia after hypomethylating agent failure
Vu H Duong, Najla Al Ali, Ling Zhang, et al.
Page
of 22
Search research articles
Search
Showing results (61-70 of 212) with videos related to
Sort By:
Page
of 22
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 3, 2006
Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes
Gary J Schiller, James Slack, John D Hainsworth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 20, 2008
Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes
Mikkael A Sekeres, Jaroslaw P Maciejewski, Aristotle A N Giagounidis, et al.
British Journal of Haematology
|
June 25, 2013
Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes
Rami S Komrokji, Azra Raza, Jeffrey E Lancet, et al.
American Journal of Hematology
|
August 25, 2019
Driver mutation-specific clinical and genomic correlates differ between primary and secondary myelofibrosis
Andrew T Kuykendall, Chetasi Talati, Eric Padron, et al.
American Journal of Hematology
|
November 4, 2018
Genetically inspired prognostic scoring system (GIPSS) outperforms dynamic international prognostic scoring system (DIPSS) in myelofibrosis patients
Andrew T Kuykendall, Chetasi Talati, Eric Padron, et al.
Plos One
|
April 18, 2012
Erythropoietin receptor signaling is membrane raft dependent
Kathy L McGraw, Gwenny M Fuhler, Joseph O Johnson, et al.
American Journal of Hematology
|
April 26, 2014
Phase II clinical study of erlotinib for treatment of myelodysplastic syndromes
Rami S Komrokji, Eric Padron, Daohai Yu, et al.
Cancer Control : Journal of the Moffitt Cancer Center
|
January 24, 2007
Cost effectiveness of lenalidomide in the treatment of transfusion-dependent myelodysplastic syndromes in the United States
Thomas F Goss, Agota Szende, Caroline Schaefer, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
August 14, 2016
Eltrombopag Use in Patients With Chronic Myelomonocytic Leukemia (CMML): A Cautionary Tale
Hanadi Ramadan, Vu H Duong, Najla Al Ali, et al.
Leukemia & Lymphoma
|
April 21, 2020
A sequential two-stage dose escalation study of eltrombopag in patients with myelodysplastic syndrome and thrombocytopenia after hypomethylating agent failure
Vu H Duong, Najla Al Ali, Ling Zhang, et al.
Page
of 22